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The aim of this paper is to introduce the subject of chirality within pharmaceuticals and its implications
in environmental contamination. The paper describes contemporary techniques and stationary phases in
the analysis of chiral pharmaceuticals and illicit drugs, the main focus being on liquid chromatography
coupled with mass spectrometry. A critical review of the methods employed including sample collection,
preparation and analysis is undertaken. Special attention is paid to the possible analytical pitfalls of
chromatographic separations at enantiomeric level, which could potentially lead to erroneous
measurements of enantiomers. Several applications of chiral analysis and results gained in the ﬁeld
are also discussed. Among them are: (i) study of fate and effects of chiral pharmaceuticals in the
environment and during wastewater treatment, (ii) estimation of community-wide drugs use via newly
emerging ﬁeld of sewage epidemiology and (iii) usage of chiral drugs as chemical markers of water
contamination with sewage. The paper also aims to identify gaps within current knowledge.
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Pharmacologically active compounds (PACs) are widely regarded
as emerging contaminants and many of them possess at least one
stereogenic centre. The aim of this paper is to introduce the subject
of chirality within PACs and its implications in environmental
contamination. The paper describes contemporary techniques
utilized in the analysis of chiral contaminants and provides a critical
review of the methods employed and results gained in the ﬁeld.
1.1. Phenomenon of chirality
Enantiomers are molecular entities which are non-superim-
posable mirror images. The chirality (handedness) of enantiomeric
molecules is caused by the presence of one or more chiral elements
(chirality axis, chirality plane, or chirality centre, e.g., asymmetric
carbon atom) in the structure. The chirality and optical activity of
the enantiomers is determined by their absolute conﬁguration, i.e.,
the spatial arrangement of the atoms in the molecule.
1.2. Nomenclature
IUPAC approved naming system is the Cahn-Ingold and Prelog
designation for four- and six-coordinate stereogenic centres, pre-
ﬁxed with R or S, or Rp or Spwhen discussing molecules with planar
chirality [1]. Dextro and Levo (+/) may also be used to describe
enantiomers where the absolute conﬁguration may not be known
or to describe the rotation of light under prescribed conditions,
although the preﬁxes ‘d’ and ‘l’ are discouraged [1]. Readers may
also encounter E1, E2, etc. in papers regarding the chromatographic
separation of enantiomers. These ad hoc preﬁxes only indicate the
elution order of the enantiomers under the presented chro-
matographic conditions when the Cahn-Ingold and Prelog and
rotatory designations are not known.
The composition of enantiomers can be calculated and expressed
in three different ways and thus data conveying this proportion
should be carefully interpreted accordingly (see Eqs. (1)–(3)):
e:e: ¼ 100ðFðþÞ  FðÞÞ (1)
where e.e. represents Enantiomeric Excess and F the mole fraction,
this is an expression of the difference between the total weight, or
mole, of each enantiomer [1], often expressed as a percentage. If
the elution order is not known, F(+) and () may be substituted for
E1 or E2 under deﬁned chromatographic conditions:
ER ¼ þ (2)
where ER represents enantiomeric ratio (the difference in the
proportion of the enantiomers expressed as a ratio) [1].
EF ¼ ðþÞðþÞ þ ðÞ (3)
where EF represents enantiomeric fraction, (+) and () may be
substituted with E1 and E2 if the elution order is not known.
Thus a racemate can be expressed as e.e. = 0%, EF = 0.5 or ER = 1.
Although the enantiomeric ratio is a widely recognized way of
presenting enantiomeric signature, the enantiomeric fraction is
gaining in popularity due to more meaningful representation of
environmental data [2].
Resolution of enantiomers is deﬁned as ‘‘the separation of a
racemate in the component enantiomers’’ [1]. In chromatography
this is usually calculated with the use of the following equation
(Eq. (4)):
Rs ¼ tr2  tr1
0:5ðw1 þ w2Þ (4)where Rs represents resolution between two symmetrical peaks, tr2
the elution time of enantiomer E2, tr1 the elution time of
enantiomer E1, w1 the base width of peak for E1 and w2 represents
the base width of peak for E2. More detailed discussion on Rs
calculation can be found elsewhere [3].
Accuracy and precision relies on full separation of enantiomers.
Unfortunately in practice, quantiﬁcation of enantiomers of chiral
contaminants is often performed using partially resolved peaks.
The two main techniques used to integrate partially resolved peaks
are the valley drop and the deconvolution method. The most
popular, the valley drop method, simply separates any non-
separated areas of the peaks with a vertical line. The deconvolution
method uses Gaussian based functions ﬁtted to each peak
individually. The valley drop method biases results towards a
more racemate fraction, as overlapped regions from larger peaks
are disproportionately ascribed to smaller peaks, particularly if
tailing occurs. The deconvolution method eliminates this bias
between uneven peaks and can even account for tailing if
appropriate software is used [4].
1.3. Chirality in pharmaceuticals
Two enantiomers of the same compound, despite having the
same physical and chemical properties, show different interactions
with other chiral molecules due to differences in spatial arrange-
ment of the atoms and therefore binding afﬁnity. This phenome-
non is particularly signiﬁcant in biological interactions as all
proteins, enzymes and carbohydrates are chiral [10]. Thus
organisms might respond uniquely to each enantiomer, a
phenomenon discovered by Pasteur in 1857 [5]. This is of
particular importance in the case of chemicals such as PACs and
pesticides, which are designed to illicit biological action.
Many drugs are chiral with well documented stereoselective
pharmacodynamic responses in humans such as those summarized
in Table 1. A drug’s pharmacological action is dependent on its
pharmacokinetics, i.e. absorption, distribution, metabolism and
excretion. These processes require interaction with many chiral
molecules within an organism. For example albumin, the major
protein responsible for transporting pharmaceuticals within the
blood is chiral therefore stereoselective transportation may occur. In
addition metabolism may result in chiral inversion (common among
anti-inﬂammatory drugs), or the addition of a chiral centre into an
achiral parent compound (for example metabolism of cimetidine
leading to the chiral metabolite, cimetidine S-oxide). Table 2
summarizes some examples of these phenomena in humans.
For a more detailed discussion see a critical review by Kasprzyk-
Hordern [6].
1.4. Implications of chirality in pharmaceuticals to risk assessments
and drug development
Because of the often wide ranging implications of the
enantiomeric composition of a drug each enantiomer is assessed
individually during drug design. In addition, the enantiomeric
fraction is measured at each step throughout the patient’s
exposure to ascertain any chiral inversion or stereoselective or
stereospeciﬁc pharmacokinetics which may take place.
However environmental risk assessments have lagged behind
those required in medicine. The European Medicines Agency
(EMEA) Guideline On the Environmental Risk Assessment of
Medicinal Products for Human Use [19] states that estimation of
exposure and the prediction of risk, Phase’s 1 and 2A of the EMEA
guideline, is only conducted on whole parent compounds i.e. as a
racemate or as a single enantiomer if prescribed as such. This is an
inappropriate risk assessment as parent compounds do not enter
the environment in their original racemic or enantiomerically pure
Table 1
Examples of stereoselective pharmacodynamic responses in human pharmaceuticals.
Drug or group of drugs Enantiomer Stereoselective pharmacodynamic response in humans
Thalidomide S() Teratogenic, inhibits the release of TNF-a from stimulated mononuclear blood cells [7]
R(+) Sedative [8]
b-Blockers, e.g. propranolol S() 100 times more antagonistic effect on b-adrenergic receptors than R(+) enantiomer [6]
Sympathomimetic drug-selective
b-adrenergic receptor
antagonists, e.g. salbutamol
R() Responsible for the bronchodilatory pharmacological affect [9]
S(+) No pharmacological effects [9]
Barbiturates S() Hypnotic and/or sedative [6]
R(+) Inactive or excitatory [6]
Citalopram R() Non active and inhibits S(+)-enantiomer [10]
S(+) Pharmacologically active as a selective serotonin reuptake inhibitor [10]
Dobutamine S() a-Adrenergic receptor agonist activity [11] resulting in vasoconstriction and dilated pupils
R(+) Binds to a-adrenergic receptor, although no activity so acts as a competitor to S().
b-Agonist resulting in inotropic and chronotropic responses [11]
1,4-Dihydropyridines S() Calcium channel agonist resulting positive inotropic and vasoconstriction response [12]
R(+) Calcium channel antagonist resulting in vasodilation and at high doses negative inotropic effects [12]
Pencillamine S() Anti-arthritic pharmacological action [6]
R(+) Extreme toxicity [6]
Ibuprofen S() 110 times more potent at COX 1 and 2 inhibition than R(+) [6]
R(+) Acts as a pro-drug through chiral inversion [6]
MDMA S(+) Greater 5-HT release, resulting in amphetamine-like response [13]
R() More hallucinogenic [13]
Ephedrine/pseudoephedrinea 1S,2S(+)-pseudoeph. Weaker CNS effects, decongestant [14]
1R,2R()-pseudoeph. Similar activity of b1,2 and 3 adrenoceptors as corresponding enantiomer [15]
1R,2S()-ephedrine Bronchodilator and abused stimulant [14]
1S,2R(+)-ephedrine Weak activity on b1,2 and 3 adrenoceptors [15]
a Ephedrine/pseudoephedrine has two chiral centres and as a result two pairs of enantiomers. The ephedrine enantiomers have a diastereomeric relationship with
pseudoephedrine enantiomers.
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wastewater treatment process, which utilizes microorganisms.
Thus the exposure and risk associated with enantiomers with
widely disparate potency and toxicity are being over or under
estimated. Only if a medicinal product breaches standards required
at these Phases 1 and 2A does it proceed to Phase 2B where
assessment of metabolites, contributing to equal or greater than
10% of the excreted product occurs. Even at this extended phase
transformation within the environment is ‘‘not further considered
here and is subject to expert judgment’’ [19]. There is no mention of
enantiomers being assessed separately at any point in the
document.
Ecological risk assessments are inherently complicated due to
interspecies differences in pharmaco-dynamics and kinetics; this
is further convoluted in risk assessments of chiral compounds. This
is because different species could potentially respond to each
enantiomer differently. For example S()-propranolol is preferen-
tially cleared in dogs whereas R(+)-propranolol is favoured in
humans [20,21]. Stanley et al. [22,23] have demonstrated that
Daphnia magna and Primephales promelas respond differently to
propranolol [23] and ﬂuoxetine [22] enantiomers. S()-proprano-
lol and S(+)-ﬂuoxetine were found to be more toxic to PrimephalesTable 2
Examples of stereoselective pharmacokinetic responses in human pharmaceuticals.
Drug or group of drugs Enantiomer Stereoselective pharmac
Propranolol S() Does not bind as well to
R(+) In vivo inversion to race
Warfarin R() Preferentially metaboliz
Ketoprofen S() Preferentially binds to a
R(+) Undergoes chiral invers
Ibuprofen S() Does not undergo chira
R(+) Inverted to S() enantio
Carvone R() Metabolized to 4S,6S(
S(+) Metabolized to 4S,6S(+)
Propranolol S() Preferentially bounds to
R(+) Preferentially eliminate
distribution due to prefpromelas than their respective enantiomers. Such an effect was not
observed in the case of Daphnia magna, possibly due to a lack of
suitable receptors. De Andres et al. [24] studied enantiomer-
selective toxicity of isomers of dopa, ﬂuoxetine and atenolol
towards Daphnia magna, Pseudokirchneriella subcapitata and
Terahymena thermophila. Toxicities observed depended on enan-
tiomer and test organism. This growing evidence for enantiomer-
selective toxicity of chiral PACs towards aquatic organisms
provides a strong basis for revision of the currently utilized
environmental risk assessment protocols. Enantiomer-selective
biotransformation has also been demonstrated by Brooks et al. [25]
for propranolol in Rainbow Trout, although not for ibuprofen or
ﬂuoxetine.
Recent advances in pharmaceutical legislation requiring risk
assessments to be undertaken for chiral pharmaceuticals at
enantiomeric level resulted in a rise of pharmaceuticals produced
in single enantiomeric forms [26]. Single enantiomers simplify the
human toxicology proﬁle and can have numerous beneﬁts such as
reduced side effects and/or reduced dosage requirements [5].
Exceptions to this include older pharmaceuticals, those too
expensive to produce as single enantiomers, drugs which require
both enantiomers and illegally produced drugs. However, it shouldokinetic response in humans
 plasma proteins [6]
mate [6]
ed and bound to albumin [16] therefore excreted quicker than S(+)-enantiomer
lbumin resulting in lower free concentration in plasma than R(+) [5]
ion to S() [6]
l inversion [6]
mer [6]
)carveol and then to 4S,6S()-carveol-glucuronic acid (half-life = 7.8 min) [17]
-carveol only (half-life = 19.4 min) [17]
 a1-acid glycoprotein rather than albumin [18]
d from humans, although same half-life as S() due to larger volume of
erential protein and/or tissue binding [18]
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marketed in enantiomerically pure form, might occur and it might
result in a mixture of enantiomers of parent drug and/or its
enantiomers being excreted, which can signiﬁcantly complicate
environmental risk assessment.
1.5. Enantioselective fate of chiral pharmaceuticals in the
environment
There are two main pathways in which pharmaceuticals ﬁnd
their way into the environment, either through disposal (house-
holds, manufacturing or landﬁll sites) or through excretion by
humans (and/or animals) into the sewage system or directly into
the environment. Disposed drugs will usually be found in the
environment in their parent form, either as a racemate or single
enantiomer, whereas excreted drugs will normally occur as a
mixture of enantiomers and predominantly as (chiral) metabolites
of the parent compound. If the point of entry to the environment is
via the sewage system the compounds are then exposed to abiotic,
non-chiral processes, such as photo-degradation and sorption, etc.
which will alter the total concentration but not their enantiomeric
composition. They will also be exposed to biotic processes, usually
microbial, which might be enantiomer-speciﬁc and/or enantiose-
lective and can alter the enantiomeric fraction of the compounds
present. In addition, degradation of achiral compounds into chiral
by-products may occur [6,27–30]. Thus WWTP efﬂuent discharged
into the environment often contains drugs which are not in the
same enantiomeric form as the administered parent compound.
Considering the potentially serious effects of biochemically
weathered PACs can have on biota, including humans, it is
surprising that environmental researchers have, until recently,
neglected the environmental fate of them.
As demonstrated above, enantiomers are treated as different
drugs by the pharmaceutical industry due to their often different
pharmacokinetic and pharmacodynamic properties. Environmen-
tal analysis and risk assessment has been slow to catch on to this
phenomenon, however a small number of groups have been
developing techniques and methods to assess the enantiomeric
composition of pharmaceuticals in WWTPs and the environment,
as listed in Table 3. This information in conjunction with
enantioselective ecotoxicological data could provide a more
realistic and informative risk assessment.
2. Analytical methodology utilized in the detection of chiral
pharmacologically active compounds in the environment at
enantiomeric level
Several methods have been developed to study the enantiomer-
ism of drugs in the environment. Table 3 summarizes the techniques
used to analyse chiral pharmaceuticals in environmental samples
and focuses on aspects of the methodology which are unique or
important to chiral analysis. Chiral analysis of environmental
matrices poses a signiﬁcant analytical challenge and has different
requirements to commonly used achiral reverse phase liquid
chromatography; it requires robust protocols designed for this type
of analysis to avoid erroneous results. The most important
advantages and pitfalls of methodological procedures utilized in
environmental chiral analysis are discussed below.
2.1. Sample collection
Sample collection, although often overlooked, should be
considered as a crucial step in any analytical protocol. A critical
evaluation of several sample collection and preparation method-
ologies utilized in the analysis of drugs of abuse in environmental
matrices such as surface water and wastewater has beenundertaken by Baker and Kasprzyk-Hordern [31] and Ort et al.
[32]. This stage in an investigation is potentially the largest source
of error and yet, this aspect of the overall analytical protocol is
under-investigated and only limited attention is usually paid to
this topic.
An important parameter not yet included as a key criterion in
method validation protocols is the stability of analytes in
environmental matrices. The manuscript by Baker and Kaspr-
zyk-Hordern [31] emphasizes that even well-established sample
collection protocols utilizing for example 24 h-composite samplers
(e.g. to collect wastewater) can introduce signiﬁcant errors,
resulting from degradation of analytes, as even a storage
temperature of 4 8C does not eliminate microbial activity. Although
the manuscript describes only non-chiral methodologies, it is easy
to extrapolate the results to chiral methods, as microbial processes
are known to be enantioselective (and/or enantiospeciﬁc) [31]. It
can be hypothesized that any biodegradation during sample
collection could affect enantiomers of the same compound to a
different extent, leading to erroneous assessment of relative
concentration of enantiomers. The chiral antidepressants dis-
cussed in the paper: nortriptyline, ﬂuoxetine, norﬂuoxetine and
venlafaxine, were found to be highly unstable in wastewater [31].
The process was more time and pH than temperature dependent
with a concentration change (due to either degradation or
formation) reaching 50% after 24 h at pH 7.4 and a temperature
of 2 8C [31]. Furthermore comparisons of grab samples from
inﬂuent and efﬂuent wastewater indicate enantioselective degra-
dation of some of these compounds during wastewater treatment
[33–35]. Therefore, degradation could also be observed during
prolonged sampling protocols leading to inaccurate results,
especially in the calculation of enantiomeric fractions.
Grab sampling is the most popular method for quantifying
chiral drugs at enantiomeric level (see Table 3). Although grab
sampling is not recommended as a sampling technique to study
fate of pollutants in the environment (as it is susceptible to short
term variations in sample concentrations), it has one advantage:
quick sample collection reduces the possibility of stereoselective
degradation during and, with correct storage procedures, after
sampling.
To summarize, in order to gain accurate and representative
concentrations of target compounds and their enantiomeric
fractions it is vital that the sample is kept in identical conditions
as it was found in situ; and minimize both abiotic and biotic
processes to prevent any further degradation and/or change in the
degradation processes. The minimization of biotic processes known
to be responsible for enantioselective transformation is of the
greatest importance in chiral analysis. This is often done by
minimizing the time between sampling and sample preparation
and lowering the temperature during transport and storage to
reduce microbial action, but may also involve other steps, such as
maintaining anaerobic conditions, in order to preserve the microbial
population dynamics. However, as discussed above such measures
might not be satisfactory. Acidiﬁcation of the sample or an addition
of sodium azide to stop microbial activity could be also imple-
mented. However any modiﬁcation of sample matrix might
introduce additional errors, e.g. a decrease of pH in the case of
ionic/ionizable molecules might change their partitioning/sorption
to solids such as suspended particulate matter, sediments or sludge.
2.2. Sample preparation
Preliminary sample preparation is targeted to the matrix
involved. Pharmaceuticals on solid matrices require extraction into
a liquid medium, often using microwave assisted extraction [53],
sonication [54] or accelerated solvent extraction [55,56]; whilst
liquid matrices may require ﬁltration to remove particulates. The
Table 3
Contemporary methods employed in the detection of chiral pharmaceuticals in environmental matrices.
Target and matrix Sample collection Sample preparation Analysis Validation Ref
Liquid chromatography
Azole antifungals (econazole,
ketoconazole, miconazole,
tebuconazole, and propiconazole)
in wastewater efﬂuent
 40L 4h composite sample, stored in
amber glass without headspace with
0.5g/L sodium azide
 Transported on ice
 Stored at 4 8C for 48h
 Filtration through GF/F 0.7mm
 SPE (Oasis HLB), elution with MeOH
 Evaporation under N2
 Reconstitution to a known volume in
10:90 MeOH:H2O
 HPLC-ESI(+)QqQ
 Two columns used for differing
analytes:
(i) ketoconazole
 Column: HSA, 2100mm, 5.0mm
 Isocratic
 Mobile phase (pH 7): ACN:H2O
(10:90), 10mM NH4OAc
 Flow: 0.25mLmin1
 Temp: 25 8C
 Inj. Vol: NR
(ii) econazole, miconazole,
tebuconazole, and propiconazole
 Column: AGP, 4100mm, 5.0mm
 Gradient
 Mobile phase (pH 7): (15% B to 30% B),
A: 100% H2O, 10mM NH4OAc, B:
100% ACN
 Flow: 0.3mLmin1
 Temp: 25 8C
 Inj. Vol.:NR
 Standard EF=0.50.007
 IDL =NR; IQL =5–25pg
 Wastewater: MQL=0.3–10ng L1; SPE
REC=77–101.6%
 Sludge: MQL =3–29ng/g; SPE
REC=71.2–94.9%
[39]
Azole antifungals (econazole,
ketoconazole, miconazole,
tebuconazole, and propiconazole)
in sludge
 Grab samples collected and wrapped
in aluminium and sealed in
polyethylene bags
 Transported on ice
 Stored at 20 8C
 Lyophilization and homogenization,
followed by ultrasound extraction
 Dilution in water followed by
procedure described above
Fluoxetine and norﬂuoxetine
in wastewater
inﬂuent and efﬂuent
 Grab samples collected in amber glass
bottles, ﬁltered3h
 Stored at 2 8C30h
 Filtration through GF/F, adjustment to
pH4
 SPE (Evolute CX-50), elution with
MeOH: 25% NH4OH (95:5)
 Evaporation to dryness
 Reconstitution in mobile phase
 Filtration through 0.45mm syringe
ﬁlters
 HPLC-ESI(+)QqQ
 Column: AGP, 2100mm, 5mm
 Isocratic
 Mobile phase (pH4.4): 10mM NH4OAc
and ACN (97:3)
 Flow: 0.22mL/min
 Temp: ambient
 Inj. Vol.: 10mL
 Standard ER=NR
 IQL=NR
 MDL=1–3pM; MQL=3–14.3pM; SPE
REC=65–82%
[38,42]
Atenolol, carbamazepine, celecoxib,
citalopram, clarithromycin,
codeine, diclofenac, erythromycin,
gemﬁbrozil, ketoprofen,
metoprolol, naproxen, paroxetine,
propranolol, sotalol, temazepam,
triclosan, trimethoprim in
wastewater efﬂuent
 35–51 day composite samples
collected on a POCIS (polar organic
chemical integrative sampler).
 Transported on ice
 Stored at 20 8C
 POCIS (Oasis HLB), elution with MeOH
 Filtration, method NR
 Rotary evaporation to 5–10mL
 Filtration through 0.22mm PTFE ﬁlters
 Evaporation to dryness under N2
 Reconstitution in 1mL MeOH
 2D-LC-ESI(+)QqQ or 2D-LC-ESI()QqQ
(i) Temazepam: Chiralpak AD-RH
column 4.6150mm, 5mm
 Mobile phase: NR
 Flow: NR
 Temp NR
 Inj vol NR
(ii) clarithromycin, codeine, diclofenac,
erythromycin, gemﬁbrozil,
ketoprofen, metoprolol, naproxen,
paroxetine, propranolol, sotalol,
triclosan: Chirobiotic V 4.6250mm,
5mm
 Isocratic
 Mobile phase (pH 4): MeOH:H2O
(90:10) with 20mM NH4OAc, 0.1%
HCOOH
 Flow: 0.5mL/min
 Temp: NR
 Inj.Vol.: NR
Quantiﬁcation carried out by non-chiral
methodology
[54,43]
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Atenolol, metoprolol, nadolol,
pindolol, propranolol, sotalol,
citalopram, ﬂuoxetine, salbutamol in
wastewater inﬂuent and efﬂuent
 Grab samples collected in amber
bottles
 Transported on ice
 Stored at 4 8C24h
 Filtration through 1.2mm, then
0.7mm glass ﬁbre ﬁlters
 SPE (Oasis HLB) elution with MeOH
 Extracts dried with Na2SO4
 Filtration through 0.22mm syringe
ﬁlters
 Evaporation to dryness under N2
 Reconstitution: NR
HPLC-ESI(+)QqQ
Column: Chirobiotic V 4.6
250mm, 5mm
 Isocratic
 Mobile phase (pH 4): MeOH:H2O
(90:10) with 20mM NH4OAc,
0.1% HCOOH
 Flow: 0.5mL/min
 Temp: NR
 Inj.Vol.: 25mL
 Standard ER=0.491 0.007–
0.511 0.007.
 Inﬂuent: IQL = 1–13ng/L, MDL =0.4–
7.5 ng/L, MQL=1–25ng/L; SPE
REC=561–1157
 Efﬂuent: IQL = 0.4–2.5 ng/L
MDL=0.2–7.2 ng/L, MQL =1–24ng/L; SPE
REC=284–1154
[37]
Amphetamine, methamphetamine,
MDMA, MDA, MDEA, ephedrine,
pseudoephedrine, norephedrine
and venlafaxine in inﬂuent and
efﬂuent wastewater
 2.5 L grab samples collected in
silanised amber bottles
 Filtration through GF/D 2.7mm and
then through GF/F 0.7mm ﬁlters.
 SPE (Oasis HLB), elution with MeOH
 Evaporation to dryness
 Reconstitution in mobile phase
 Filtration through 0.2mm PTFE ﬁlters
 UPLC-ESI(+)QqQ
 Column: CBH 2100mm, 5mm
 Isocratic
 Mobile phase: H2O:IPA (90:10)
and 1mM NH4OAc
 Temp: 25 8C
 Inj.Vol.: 20mL
 IQL =0.4–1.25mg/L; IDL=0.1–0.4mg/L
 Inﬂuent: MDL=0.55–3.5ng/L;
MQL=2.25–11.75ng/L; SPE
REC=21.30.5–124.3 0.6%
 Efﬂuent: MDL=0.6–1.7 ng/L;
MQL=2.8–10.1 ng/L; SPE
REC=54.1 0.9–122.46.1%
[36]
Amphetamine, methamphetamine,
MDA, MDMA, propranolol,
atenolol, metoprolol, ﬂuoxetine
and venlafaxine in river water
and sewage efﬂuent
 Grab samples collected in 1L
polypropylene bottles and stored on
dry ice
Filtration through GF/F
 SPE (Oasis HLB), elution with MeOH
 Evaporation under N2
 Reconstitution in mobile phase
 Filtration through 0.2mm syringe
ﬁlter
 UPLC-ESI(+)QTOF
 Column1: Chirobiotic V 250
2.1mm, 5mm
 Isocratic
 Mobile phase: MeOH, 4mM NH4OAc
and 0.005% HCOOH
 Flow: 0.1mLmin1
 Temp: 25 8C
 Inj.Vol: 20mL
 Column2: CBH 1002mm, 5mm
 Isocratic
 Mobile phase: H2O: IPA (90:10)
and 1mM NH4OAc
 Temp: 25 8C
 Inj.Vol.: 20mL
Chirobiotic V:
 IQL =0.5–15mg/L
 IDL =0.2–3mg/L
 River: MDL=0.2–10.4ngL1;
MQL=0.3–39ng/L
 Efﬂuent: MDL=0.6–22.8ng/L;
MQL=1.3–85.7ng/L
 SPE REC=64–119%
CBH:
 IQL =5–25mg/L; IDL=1.25–5mg/L
 River: MDL=2.1–10.7ng/L;
MQL=9.1–51.7ng/L; SPE REC=77–
138%
[44]
Venlafaxine, O-desmethylvenlafaxine,
N-desmethylvenlafaxine,
O,N-didesmethylvenlafaxine,
N,N-didesmethylvenlafaxine,
tridesmethylvenlafaxine
in laboratory scale bioreactors,
wastewater, activated
sludge and surface
 Grab samples collected, transported
and stored refrigerated 30h
 Extracts stored1 week
 SPE (Oasis HLB), elution with MeOH
 Evaporation to 3mL and then to
5mL with water
 LC-ESI(+)QqQ
 Chirobiotic V 4.6250mm, 5mm
 Isocratic
 Mobile phase: 15:85 NH4OAc:MeOH,
pH 6at 1mL/min
Quantiﬁcation carried out by non-chiral
methodology
[32]
Amphetamine, methamphetamine,
ephedrine, pseudoephedrine,
MDA, MDMA, venlafaxine,
atenolol in wastewater inﬂuent,
efﬂuent and surface water
samples in
 Grab samples collected in silanised
amber glass jars with Teﬂon faced
phenolic caps
 Filtration through 2.7mm then 0.7mm
glass ﬁbre ﬁlters
 Adjustment to pH 7.5 with NaOH
 SPE (HLB); elution with MeOH
 Evaporation to dryness with N2
 Reconstitution in mobile phase for EF
analysis
 LC-ESI(+)QqQ
 Column: CBH 1002mm, 5mm
 Isocratic
 Mobile phase: 90:10 H2O:IPA,
1mM NH4OAc
 Temp: 25 8C
 Inj Vol: 20mL
Quantiﬁcation carried out by non-chiral
methodology
[45,41]
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Table 3 (Continued )
Target and matrix Sample collection Sample preparation Analysis Validation Ref
Pantoprazole, lansoprazole,
omeprazole
 Grab samples collected in amber glass
bottles, transported on ice.
 Filtered through 0.45mm glass ﬁbre ﬁlters,
 3 drops of MeOH added to each 1 L
 Stored at 4 8C
None, direct injection of aqueous sample LC-ESI(+)IT
 Column 1: RAM-BSA 504.6mm
 Mobile phase: 35:65 ACN:H2O at
1mL/min.
 Column 2: tris-(3,5-
dimethoxyphenylcarbamate) of
amylose coated on to APS-Nucleosil
(non-commercial) 1504.6mm
 Isocratic
 Mobile phase: 35:65 ACN:H2O
at 1mL/min
 Temp: 25 8C
 Inj Vol: 20mL
LOD=0.15 and 2.0mg L1
LOQ=0.4 and 0.6mg L1
[43,44]
Metoprolol  6h Composite samples containing 0.1%
NaN3 transported to lab after max 2 days
Filtered through 1–3mm glass ﬁbre
ﬁlters
 pH adjusted to 2 with H2SO4
 SPE (Oasis MCX); eluted with 21mL
MeOH then 31mL 2% NH4OH in
MeOH
 Evaporation to dryness with N2
 Reconstituted in 500mL H2O:ACN
70:30 v:v and 2.5mM acetic acid
UPLC-QqQMS/MS
 Column: AGP 1102mm, 5mm
 Isocratic
 Mobile Phase: 98:2 H2O:ACN with
10mM NH4OAc
Quantiﬁcation carried out by non-chiral
methodology
[55]
Gas chromatography
O-Desmethyl naproxen in
river water, urban drain
water, mangrove water
and sewage efﬂuent
 Grab samples collected by a ‘‘sampling
device’’ designed by group in 2.5 L
amber glass bottles
 Filtration through GF/A
 SPE (Oasis HLB), elution with
methanol
 Evaporation to dryness
 Reconstitution NR
 Derivatisation with MCM
 GC-IT (direct analysis)
 Column: Hydrodex-b-6TBDM
 Mobile phase: He at 12 PSI
 Temp.: ramped from 70 8C to 221 8C
 Inj.Vol.: NR
N/R [30]
Ibuprofen, ketoprofen and
naproxen in surface water
and wastewater efﬂuent
 Grab samples collected in 1 L amber
bottles
 Centrifugation
 Filtration through GF/F
 Acidiﬁcation to pH 2.5 with H2SO4
 SPE (Oasis HLB), elution with
acetonitrile
 Concentration under vacuum
centrifugation
 Derivatisation with TEA and ECF
 SPE (Oasis HLB); elution in ethyl
acetate
 GC-(EI)QqQ (indirect analysis)
 Column: HP5-MS 30m 
0.25mm, 0.25mm
 Mobile phase: 0.8mL/min He
 Temp: ramped from 120 8C to 300 8C
 Inj.Vol.: 1mL
 Standard EF=0.48 and 0.49
 IQL and IDL=NR
 MDL=0.2–3.3ng/L; MQL=NR; SPE
REC=NR
[48]
Ibuprofen, ketoprofen,
naproxen in drinking water
and synthetic efﬂuent
 N/A  SPE (Oasis HLB), elution with MeOH
and MeOH:MTBE (1:9)
 Concentration under vacuum
 Centrifugation
 Derivatisation with TEA and ECF
 SPE (Oasis HLB); elution in ethyl
acetate
[49]
Metoprolol and propranolol
in wastewater efﬂuent
and river water
 WWTP: 24h composite samples
 River water: grab samples using LDPE
bottles in 1 L glass
 Transported on ice overnight, ﬁltered
with 12h, stored at 5 8C, extracted 5
days
 SPE (C18), elution with MeOH
 Drying in vacuum oven at room
temperature overnight
 Reconstitution in MeOH
 Evaporation to dryness under N2
 Derivatisation with MSTFA and
()MPTA-Cl at room temperature
and 60 8C
 Dilution with isooctane
 GC-IT (indirect analysis)
 Column: MDN-5S 30m
0.25mm, 0.25mm
 Mobile phase: 1mL/min He
 Temp: ramped from 100 8C to 300 8C
 Inj.Vol.: 1mL
 IQL and IDL=NR
 MDL=10ng/L ‘‘typical’’; MQL=NR;
SPE REC=48%
[31,50]
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S.E. Evans, B. Kasprzyk-Hordern / Trends in Environmental Analytical Chemistry 1 (2014) e34–e51 e41aims of sample preparation are twofold; ﬁrstly to reduce the
matrix effects, of particular importance when using chiral LC–
MS(ESI) as it can be subject to signiﬁcant matrix effects; secondly,
to concentrate the pharmaceuticals in order to increase the
sensitivity of the analytical technique chosen. This clean-up and
concentration of a sample is often carried out through solid phase
extraction (SPE) or a variant of this technique such as solid phase
micro-extraction (SPME). The choice of SPE sorbent is speciﬁc for
the compounds of interest. For multiple target analytes, or non-
targeted analysis, a compromise will be made to gain the best
overall recovery. Solvent type and pH impact the recovery and also
potentially chromatographic separation so method development
should explore a variety of solvents. As an example, the authors
found that eluting basic compounds with the use of 7% ammonium
hydroxide in methanol, required by a mixed-mode cation
exchange SPE phase (Oasis MCX), drastically reduced the
chromatographic resolution of enantiomers of almost all the
compounds trialled (amphetamines, beta blockers, antidepres-
sants, analgesics, bronchodilators) when using two different chiral
columns (CBH and Chirobiotic V). This is despite evaporation of
extracts and reconstitution of dry residue in mobile phase.
Consequently an alternative SPE phase (Oasis MAX or HLB)
utilizing only methanol as an eluting agent was used (unpublished
results and [33]). Matrix effects are of key importance in chiral
separations as they might not only cause different signal
suppression of a pair of enantiomers in the ESI but they might
also signiﬁcantly affect chiral recognition. Therefore the choice of
SPE sorbent might signiﬁcantly impact the overall performance of
the method.
The evaluation of published literature (see Table 3) indicates
that SPE with Oasis HLB cartridges is the method of choice for
chiral separations with LCMS technique. Unfortunately, HLB is not
a selective sorbent, therefore expected matrix effects will probably
be relatively high. Recoveries obtained usually exceeded 50% and
no stereoselectivity has been observed or reported [33].
As an alternative, or even as an addition to SPE, an achiral
column can be used prior to the enantioselective analysis. This
multi-dimensional chromatography was ﬁrst used for chiral
analysis by Schomburg and Weeke in 1982 [57] and has since
been used to examine pharmaceuticals in the environment [43,44].
The initial column can comprise a traditional achiral chromatog-
raphy column, e.g. C18, which may separate otherwise co-eluting
compounds or a column which is more targeted to removal of
matrix effects (resulting from for example the presence of
macromolecules such as humic substances). These include
restricted-access media (RAM), which exclude some larger
molecules based on their size and hydrophobic or ion-exchange
interactions and allow small molecules, e.g. pharmaceuticals,
through to the chiral column [44]. Among RAM columns are: alkyl-
diol-silica (ADS), internal surface reversed phase (ISRP), semi-
permeable surface (SPS), shielded hydrophobic phase (SHP),
mixed-function phase (MFP), and protein-coated silica [43]. These
were originally developed for biological samples and food but
some of them such as bovine serum-albumin (BSA) which excludes
humic substances [43], are ideal for certain environmental
matrices.
2.3. Chromatographic analysis
Sample collection and sample preparation should not be
stereoselective, i.e. no change in the enantiomeric fraction should
occur (although chiral SPE sorbents could be used to separate
enantiomers). Liquid chromatography is the most commonly
utilized technique for chiral recognition as there are several
limitations to GC analysis. These include the requirement for
derivatisation in some cases (e.g. non-volatile compounds) and the
S.E. Evans, B. Kasprzyk-Hordern / Trends in Environmental Analytical Chemistry 1 (2014) e34–e51e42high temperatures needed, which may racemize or degrade some
compounds [58]. Despite this there are examples of successful use
of gas chromatography [27,50].
Commonly used stationary phases, such as C18 (Octadecyl
carbon chain), are achiral and cannot distinguish between
enantiomers. Therefore chiral stationary phases have to be applied.
This is referred to as direct enantiomeric separation. An alternative,
often utilized in GC is derivatisation, which is carried out using
auxiliary chiral reagents in order to convert enantiomers into
diastereomers, known as in-direct enantiomeric separation.
Diastereomers can then be separated with achiral chromatography
[28,45,47,48]. Unfortunately due to the complex matrices and very
low ppt concentrations of studied analytes, the utilization of LC–
UV is often not suitable in environmental analysis. Therefore
tandem mass spectrometry with triple quadrupole (QqQ), for
sensitive targeted identiﬁcation and quantiﬁcation of compounds,
or high resolution mass spectrometry such as QTOF, for non-
targeted analysis is often used. LC–UV methods cannot usually be
directly applied to LC–MS, therefore despite a wealth of informa-
tion and validated LC–UV methods for the detection of pharma-
ceuticals at the enantiomeric level, the ﬁeld of environmental (or
any other) analysis utilizing LC–MS has had to start from the
beginning. Some of the most important differences between UV–
Vis detection and mass spectrometry include (apart from higher
sensitivity, selectivity and variability of LC–MS methods) the use of
non-volatile buffers (e.g. phosphate buffer) or mobile phase
additives in LC–UV, which are not compatible with MS interfaces
[59] due to, for example, their lack of volatility. To overcome this,
volatile salts such as ammonium acetate or ammonium formate
are used instead, although this will have implications on the
separation of enantiomers and the chromatography and ionization
of the compounds so method development is required. Tradition-
ally chiral chromatography has often been conducted in normal
phase [58], however typical normal phase solvents are not
compatible with the widely used electrospray ionization interface
(ESI) in LC–MS/MS applications. This is also more appropriate for
analysis of compounds within polar matrices such as water. Many
commercially available columns are able to operate under a variety
of modes; however mechanistic information and method devel-
opment is still limited.
Chiral liquid chromatography coupled with mass spectrometry
is the method of choice in the analysis of chiral drugs. Examples of
other detectors such as Electron Capture Detectors, UV detectors or
circular dichroism (CD) detectors are in the minority even when
expanding the search to related ﬁelds. Detection should be non-
stereoselective. However, enantioselective ion suppression or
enhancement caused by the matrix and their physical separation
in time, common when MS utilizing ESI(+) can be observed. This
enantioselective signal suppression/enhancement can lead to
erroneous measurements (e.g. non-racemic composition for
analytes which are in actual fact racemic or vice versa). For
example, Lo´pez-Serna et al. [60] reported that in the case of several
compounds including albuterol, pindolol, clenbuterol and espe-
cially propranolol, metoprolol and timolol, increasingly complex
matrices resulted in EF values deviating from 0.5 (racemic mixture)
indicating stereoselective signal suppression. For example, EF for
propranolol-d7 was 0.5 in the standard solution, 0.58 in surface
water and 0.66 in wastewater inﬂuent.
The above phenomenon should be compensated for via the
usage of labelled analogues of standards: e.g. deuterated ISs.
Therefore, to avoid the above mentioned problems and to limit
differential instrument response for each enantiomer, the modiﬁed
Eq. (3) is recommended for EF calculation:
EF ¼ E1rel
E1rel þ E2rel
and E1rel ¼
E1
E1IS
; E2rel ¼
E2
E2IS
(5)where E1 and E2 represent peak areas of the (+) and ()
enantiomers respectively, or the ﬁrst- or the second-eluted
enantiomers under deﬁned chromatographic conditions if the
elution order is not known and E1IS, E2IS represent corresponding
peak areas of internal standards (important note: internal
standards should be labelled e.g. deuterated or C13-analogues of
analytes).
If concentrations of single enantiomers (instead of peak areas)
are used to calculate enantiomeric ratios, it is also of the greatest
importance to remember that either internal standard or standard
addition approach is required for quantitation purposes.
2.4. Chiral stationary phases
Several chiral stationary phases (CSPs) have been developed
and successfully used in drug discovery, a major driving force
behind chiral chromatography [61]. A brief introduction to generic
chiral mechanisms and detailed discussion of chiral stationary
phases reported to be used in environmental analysis of chiral
pharmaceuticals is given below. There are many comprehensive
reviews, the most up to date include [61–64].
Chiral stationary phases comprise a chiral molecule bonded to a
support, usually silica. Chromatography columns rely on a
substrate to approach the stationary phase either under a force
propelling, or pulling, it to the stationary phase surface or through
arbitrary collision with it [61]. In chiral chromatography one of the
analyte’s enantiomers is then preferentially bound to the station-
ary phase due to the spatial arrangement of the atoms; the other
enantiomer may not bind at all or, more likely, bind more weakly
than its counterpart [61]. This weaker bound enantiomer will have
a shorter transient relationship with the stationary phase and
therefore pass through the column more rapidly, under the force of
the mobile phase. This separates the enantiomers in time and
allows for stereoselective analysis. This transient diastereomeric
relationship can be described by the equilibrium Eqs. (6a) and (6b)
[61]:
ðRÞ  CS þ ðSÞ  SA !KS ½ðRÞ  CS    ðSÞ  SA	 (6a)
ðRÞ  CS þ ðRÞ  SA !KR ½ðRÞ  CS    ðRÞ  SA	 (6b)
where CS is a chiral selector i.e. the stationary phase, SA is a
selectand i.e. the enantiomer of the target compound. The
energetic differences between the two diastereomeric complexes
(right hand side species in Eqs. (6a) and (6b)), as indicated by
distinct association constants KR and KS, are the fundamental
physical basis for stereoselective retention in that chromatograph-
ic system.
2.4.1. Mechanism of chiral recognition
Easson-Stedman’s 3-contact point model [61], was the ﬁrst
theoretical explanation of the chiral recognition mechanism.
Easson and Stedman [65] proposed that a minimum of three
binding points have to occur between the enantiomer and the
substrate (in the case of chromatography the stationary phase) in
order to obtain a chiral recognition (see Fig. 1a).
The enantiomers (indicated as ‘a,b,c,d’) bind to the single
enantiomer stationary phase (A,B,C), with each letter correspond-
ing to its capital counterpart i.e. a-A, b-B and c-C. Each bond is of
differing potential in the order of a-A>b-B>c-C. The R enantiomer
is able to align three contact points resulting in a stronger bind that
S’s single a-A (preferentially formed due to the relatively high
binding potential). Flipping the S enantiomer upside down results
in steric differences, due to ‘d’, so the gap between the atoms is too
great to form bonds and the support structure e.g. silica, prevents
‘S’ from aligning from below. Within this theoretical chiral column
the R-enantiomer would preferentially bind to the stationary
Fig. 1. Two models demonstrating enantiomeric recognition: (a) the three contact point model; (b) the four contact point model [68].
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in a shorter elution time [66].
This three-point model has been expanded and reﬁned to
include differing bond lengths, the presence of eight centre
interactions through four-contact points when the chiral
selector is free ﬂowing [67], see Fig. 1b, and the notion that
the interactions between the contact points can be attractive or
repulsive [68].
Despite these reﬁnements the three-point rule is often the one
used to demonstrate chiral speciﬁcity due to its simplicity and, as
the enantiomers are only able to approach the chiral selector
from one direction in chromatography, the presence of a pocket
is often not required for stereoselectivity as outlined in the ‘4’
contact point model. It should be highlighted that three (or four)
different binding points can equate to fewer than this interac-
tions, e.g. p–p stacking will count for at least two contact points,
despite being only one interaction [69].
The types of interactions which may take place include [61]:
 Steric ﬁt, based on size and shape
 Electrostatic ﬁt e.g. ionic, p–p or H bonds
 Hydrophobic ﬁt i.e. if hydrophobic areas are spatially aligned
 Dynamic and induced ﬁt
 Mutual saturation of extended molecular surfaces
2.4.2. Types of stationary phases and their uses within pharmaceutical
environmental analysis
The main groups of chiral selectors used as chiral stationary
phases are: macromolecular selectors, macrocyclic selectors and
low-molecular mass selectors [61]. Macromolecular and macro-
cyclic stationary phases have been used in LC environmental
analysis of pharmaceuticals, whereas only macrocyclics have been
utilized in direct GC analysis within the ﬁeld. The section below
provides information on method development and lists previous
uses of columns (within the ﬁeld of pharmaceutical environmental
analysis only).
2.4.2.1. Macromolecular selectors. These protein chiral selectors
are particularly useful as they provide information on how the
molecules will behave in vivo [70], e.g. enantiomer speciﬁc binding
potential to albumin and therefore bioavailability. They have been
developed to be compatible with a wide number of mobile phases,
and therefore analytes, and have been exploited using LC within
the ﬁeld of environmental chiral analysis.
2.4.2.1.1. Cellobiohydrolase. Cellobiohydrolase stationary phase
(CBH) is a cellulase enzyme immobilized on to 5 mm silica beads
[71] with an isoelectric point of 3.9 [72]. It contains multiple
chiral centres and mechanisms for ionic, hydrophobic and
hydrogen bonding [72], for a more detailed description please
see paper by Fornstedt et al. [73]. It has been successfully
applied, using an isocratic mobile phase of H2O with 10% 2-
propanol and 1 mM NH4OH, to amphetamine-like compounds
(such as amphetamine, methamphetamine, MDMA, MDA,MDEA, ephedrine/pseudoephedrine, norphedrine) as well as
venlafaxine and atenolol in environmental samples within one
analytical run (Fig. 2) [41,42]. Good results are also often
obtained with b-receptor antagonists [73]. This column is
particularly sensitive to pH, organic content in the mobile phase
and temperature, with denaturing a very real possibility. This
limits the range of mobile phases which can be trialled as well as
the sample preparation available. However in general increased
acetonitrile or 2-propanolol concentration and pH increases
enantioselectivity whilst decreasing retention times [74],
although amines have been observed to have increasing
retention times with increasing pH [75].
High resolution time of ﬂight MS (QTOF) systems with ESI
interface often rely on high organic content mobile phases to
increase their sensitivity. As the CBH does not allow for greater
than 20% organic content this may restrict its use with QTOF. See
paper by Bagnall et al. [41] for further discussion.
2.4.2.1.2. Albumin. Albumin based stationary phases include bovine
(BSA) and human (HSA) serum. They have an isoelectric point of 4.7,
contain 2 primary binding sites, (warfarin-azapropazone and indol-
benzodiazepine) plus others of lesser importance [70], and
preferentially resolve acidic compounds. HSA has been applied to
ketoconazole analysis in environmental samples (sludge and
wastewater efﬂuent) using LC–MS/MS with an 10:90 acetonitrile:-
water with 10 mM ammonium acetate mobile phase [36].
2.4.2.1.3. a1-Acid glycoprotein. a1-Acid glycoprotein (AGP) is a
peptide chain which includes 14 sialic acid residues. It is also
sourced from human or bovine serum and is responsible for the
majority of protein binding to cationic drugs [70] and therefore
plays a crucial role in their bioavailability. Despite this biological
speciﬁcity, as a stationary phase it has been used in LC for the
separation of acidic, neutral [59] and basic drugs [35]. Azoles have
been analysed in sludge and wastewater efﬂuent using an aqueous
mobile phase modiﬁed with 10 mM ammonium acetate and
between 15% and 30% acetonitrile (gradient) [36]. Fluoxetine and
norﬂuoxetine were analysed in wastewater inﬂuent and efﬂuent
using a similar aqueous mobile phase containing 10 mM ammoni-
um acetate and 3% acetonitrile [35].
Organic modiﬁers are often added to the aqueous phase in order
to improve or elicit enantioselectivity, including methanol,
ethanol, 1-propanol, 2-propanolol and acetonitrile, as in the case
of econazole, miconazole, tebuconazole, propiconazole [36],
ﬂuoxetine and norﬂuoxetine [35]. A detailed description of method
development using this stationary phase is given by Michishita
et al. [59].
2.4.2.1.4. Amylose and cellulose. To the authors knowledge the use
of amylose and cellulose in the environmental ﬁeld is currently
limited to two applications: temazepam in treated wastewater
efﬂuent using, amylose derivative, Chiralpak AD-RH LC–MS/MS
(mobile phase not reported) [40] and the analysis of pantoprazole,
lansoprazole and omeprazole using LC-IT with a non-commercial
column based on amylose tris-(3,5-dimethylphenylcarbamate)
with 35:65 acetonitrile:water mobile phase [43,44].
Fig. 2. Mass chromatograms showing chiral drugs in wastewater obtained with CBH
column and HPLC-QqQ [44].
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carbamate) coated on to 5 mm silica gel [76], designed for normal
or reverse phase with acetonitrile, methanol, ethanol or isopro-
panol and/or water. Borate or phosphate buffers are recommended
for acidic or basic compounds in aqueous phase [76], although
ammonium based salts should be used with ESI. Studies have alsodemonstrated that additives such as triethylamine and triﬂuor-
oacetic acid can be used to assist resolution of neutral compounds
separate as well [77]. It has been noted that hydrogen bonding to
phenol groups is an important mechanisms to consider [74].
Elution times are often quicker in acetonitrile compared to ethanol
or methanol and resolution and peak width can be also greatly
affected by solvent choice [77]. For more detailed discussions on
protein based chiral stationary phases please see work by Haginaka
[70].
2.4.2.2. Macrocyclic selectors.
2.4.2.2.1. Cyclodextrins. Cyclodextrins are oligosaccharides com-
prising of between 30 and 40 chiral centres. This abundance of
chiral centres and the ability to adapt their shape to analytes,
inducing a ﬁt [61] allows for resolution of a wide variety of
analytes. They have been used in GC–MS environmental analysis
[27,50], removing the need for derivatisation. For those interested
in using cyclodextrins with gas chromatography see paper by
Schurig [78].
2.4.2.2.2. Macrocyclic glycopeptide antibiotics. There is a plethitude
of macrocyclic antibiotics all with a varying number of chiral
centres, molecular masses and isoelectric points [79]. Interested
readers should consult papers written by Ward and Ilisz [79,80].
Glycopeptides resolve a wide variety of analytes in normal, polar
organic or reversed phase modes [81]. They have a higher capacity
load than protein phases and are more stable [79], allowing greater
manipulation of conditions in order to gain enantioselectivity.
They separate enantiomers via p–p interactions, hydrogen bonds,
hydrophobic inclusion, dipole stacking and steric repulsions either
in isolation or combination [79]. For method development
information regarding glycopeptides see paper by Fernandes
et al. [82].
2.4.2.2.2.1Vancomycin. Vancomycin contains 18 stereocentres [79]
(see Fig. 3 for the structure and possible interactions). It has been
used to resolve the widest range of compounds in environmental
analysis of any chiral column, including: clarithromycin, codeine,
diclofenac, erythromycin, gemﬁbrozil, ketoprofen, metoprolol,
naproxen, paroxetine, propranolol, sotalol, triclosan atenolol,
nadolol, pindolol, citalopram, ﬂuoxetine, amphetamine, metham-
phetamine, MDA, MDMA, venlafaxine and its metabolites
[29,34,40,41,60], although notably not amphetamines (Fig. 4) [41].
Most papers report using mobile phases comprising methanol
with ammonium acetate and formic acid modiﬁer such as (i) 90%
methanol, 10% ultrapure water with 20 mM ammonium acetate
and 0.1% formic acid [34,40], (ii) 99.995% methanol modiﬁed with
4 mM ammonium acetate and 0.005% formic acid [41] or (iii)
methanol with 15% ammonium acetate, although no acid [29]. The
main drawback is the long retention times which have been
reported to be 40 min (citalopram as last eluting analyte) [34] and
39 min (atenolol as last eluting analyte) [41]. Shorter retention
times may be achieved with water as a modiﬁer, however reduced
resolution and sensitivity have been noted (unpublished results)
and the relationship between organic content and run time is not
linear [34].
2.4.3. Factors inﬂuencing chiral recognition
Chiral chromatographic method development should select
conditions in which the enantiomers have unique elution times. It
is vital that achiral factors, such as the mobile phase composition,
assist in the binding of a compound to the stationary phase but do
not overshadow the enantiomers differing binding potential i.e. a
mobile phase should allow compounds to interact and bind to the
stationary phase, but not so strongly that spatial (chiral)
conﬁguration is rendered obsolete.
Chiral stationary phases are relatively exclusive regarding their
binding potential, it may therefore be necessary to try several
Fig. 3. Potential binding sites and mechanisms in vancomycin [100].
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of many compounds in one chromatographic run, is unusual, only
the CBH [41,42], vancomycin [29,40,41,51,60] and the AGP [36]
columns have been reported to do so. This inability to undertake
multi-residue analysis is one of the most limiting factors in the
ﬁeld, particularly in screening for unknowns and studies of
transformation of chiral drugs.
There are many factors which inﬂuence the stereoselective
nature of chiral selectors. In addition to the type of chiral selector,
the density and orientation of the chiral selector within a
stationary phase are also important factors [81]. However, with
most research in the ﬁeld using commercially available columns,
there are few reports on controlled studies on these factors. Chiral
recognition interactions are transient and are dependent not only
on the compounds and stationary phase but also on the mobile
phase and other environmental factors. Focusing only on chiral
recognition factors should simplify mechanistic studies [69]
however, as it is possible for more than one recognition
mechanism to occur, accurately predicting whether enantiomers
will resolve on a stationary phase is still difﬁcult. In addition, the
effects of the mobile phase and its additives on the steric
environment of the chiral cavities in the stationary phase are also
not very clear [84]. The relationship between analytes, the mobile
phase and stationary phases is a complex one however some
patterns and relationships exist which may assist in method
development.
2.4.3.1. Chiral gas chromatography. Chiral GC efﬁciency is impact-
ed by the type and density of chiral selectors, column length, ﬁlm
thickness, temperature and gas ﬂow rate [85]. Temperature plays
an important role in GC stereoselectivity impacting the free
enthalpy (Gibbs energy) difference between the chiral stationary
phase and the enantiomers of the target analyte [85]. Most
stereoselectivity is dependent on enthalpy control; therefore the
temperature should be kept as low as possible to increase theseparation [85]. For more information on GC thermodynamics
please see [85,86].
2.4.3.2. Chiral liquid chromatography. The stationary phase com-
position (e.g. type and density of chiral selector, column length and
internal diameter, particle size) is obviously crucial to the
successfulness of the column. However because the mobile phase
in LC contributes more to the chromatographic separation, in
comparison to GC, the method development for each column and
analyte is more convoluted and complex. The main conditions
which may be manipulated, are temperature, mobile phase
composition, pH, and ﬂow rate [81].
2.4.3.2.1. Temperature. Although temperature does play a signiﬁ-
cant role in LC, its manipulation may be limited by the stability of
the chiral selector. Protein derived chiral selectors are particu-
larly sensitive to temperature changes e.g. CBH column must be
maintained at 293–298 K in order to prevent denaturation [87].
Despite this Jonsson et al. [88] raised the temperature to 328 K
on an in-house made column containing CBH I, which improved
enantioselectivity and capacity factors. Experimental work has
also been carried out at low temperatures on Chirobiotic T
column; 288 K provided signiﬁcantly better resolution than
313 K [89]. Those interested in low temperature and/or dynamic
HPLC would be advised to read paper by D’Acquarica et al.
[90].
2.4.3.2.2. Mobile phase composition. The mobile phase choice has
direct implications on the selectivity of the stationary phase in LC
and therefore must be tailored to the interactions which will take
place within the column (column speciﬁc notes are detailed
above). Relatively small changes in composition often result in
stark differences in resolution and retention time and accurate
prediction is extremely hard. Functional groups on the stationary
phase and analyte may provide a good starting point for method
development e.g. if hydrophobic groups are present then reversed
phase LC would allow for this interaction or if ionic mechanisms
Fig. 4. Mass chromatograms showing chiral drugs in wastewater obtained with Chirobiotic V column and HPLC-QTOF [44].
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mode or reversed phase.
2.4.3.2.3. pH. Manipulating the pH and therefore the charge state on
the selector and analyte can also play an important role in the chiral
separation of molecules with ionizable acidic or basic functional
groups [81]. However chiral columns often have relatively strict
limits on what pH they can withstand e.g. even the relatively robust
Chirobiotic V must be maintained within 3.5–7 pH [34].
2.4.3.2.4. Flow rate. Lower ﬂow rates lengthen retention times and
the widen peaks, however they also increase resolution which is of
the greatest importance during chiral chromatography as mass
spectrometry cannot distinguish between enantiomers. A compro-
mise between resolution and retention time must therefore be made.
Unlike newly developed UHPLC reversed-phase stationary
phases (such as <2 mm C18), commercially available chiral
stationary phases have to be run in a traditional HPLC mode under
pressures, usually, not exceeding 2000 psi. The development of
chiral stationary phases compatible with UHPLC technique would
help reduce retention times and an increase column efﬁciency.
3. The applications of enantiomeric proﬁling of
pharmacologically active compounds in environmental
matrices
Pharmaceuticals have been found in a variety of environments,
and with implications on water quality and the ecosystem, workin this ﬁeld is vital. There are ﬁve main areas where chiral analysis
of pharmaceuticals in the environment is being utilized: (i)
Enantioselective degradation of chiral PACs during wastewater
treatment, (ii) Enantioselective environmental fate of chiral PACs,
(iii) Sewage epidemiology, (iv) Chiral PACs as chemical markers of
water contamination with sewage and (v) Chiral PACs as
indicators for environmental biotransformation. All are discussed
below.
3.1. Enantioselective degradation of chiral PACs during wastewater
treatment
Wastewater is the main route for pharmaceuticals to enter the
environment. As previously discussed they often enter WWTPs in
modiﬁed form (e.g. as metabolites) and/or with the enantiomeric
fractions altered due to human metabolism. Then within the
WWTP the treatment processes, particularly biological, to which
the wastewater is subjected, further alter the state of the
pharmaceuticals (see Figs. 5 and 6). As previously mentioned,
risk assessment only assesses whole drugs in their parent forms, or
if deemed a risk, it also takes into account metabolites comprising
more than 10% of the excreted product [91]. However enantio-
meric proﬁling of the drugs within efﬂuent [27,28,33–
36,40,41,45,48,50] illustrates how inappropriate this is as chiral
drugs are found in wastewater in non-racemic forms and are
subject to stereoselective transformation during treatment.
Fig. 5. Concentrations (as symbols) and mean EF values (as bars) recorded in WWTP inﬂuent [30,36–39,45,50,51].
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logical data can help to inform a more realistic risk assessment.
There are relatively few studies which sample inﬂuent and
efﬂuent and analyse the concentrations of drugs at enantiomeric
level [27,33–36,42,47,48] and only one which has included sludge
within their study [36]. Studies to date have noted that wastewater
treatment is to a degree successful in decreasing the overall
concentration of parent compounds [27,33–36,42,47,48]. However
the extent of this success varies widely between compounds and
wastewater treatment processes studied.
Stereoselective changes during wastewater treatment were
observed in almost all compounds analysed during both activated
sludge [33,34,42,47] or trickling ﬁlters [47] treatment. For
example, in a study of 7 WWTPs utilizing activated sludge andFig. 6. Concentrations (as symbols) and mean EF values (as bars) trickling ﬁlters over the period of 9 months, enantioselective fate of
studied drugs (amphetamine-like compounds, ephedrines, antide-
pressant venlafaxine and beta-blocker atenolol) was observed.
MDMA was found in raw wastewater to be enriched with R()-
enantiomer, (mean EF recorded ðEFÞ ¼ 0:68) due to preferential
metabolism of S(+)-MDMA in humans. The treated wastewater’s
ðEF ¼ 0:78Þ indicates further enrichment of R()MDMA as a result
of wastewater treatment. The highest stereoselectivity was
observed in the case of activated sludge treatment, indicating
that different consortia of microorganisms are responsible for
degradation in different treatment processes. Amphetamine was
also found to be enriched with R()-enantiomer due to stereo-
selective WWTP processes. Weak stereoselective processes were
also observed in the case of venlafaxine at a full scale WWTP [42].recorded in WWTP efﬂuent [30,31,36–39,43–45,48,50,51,53].
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degradation of venlafaxine in lab-based microcosm experiments.
However, they reported enantioselective degradation of O-
desmethylvenlafaxine (main metabolite of venlafaxine), with
preferential removal of S-enantiomer under anaerobic conditions
although not under aerobic conditions [29].
Atenolol was found to be enriched with S()-enantiomer in
both raw and treated wastewater in three studies [40,42,92], in
contrast enrichment with R(+)-enantiomer was observed by
Kasprzyk-Hordern et al. [42]. Especially during activated sludge
treatment with no or low stereoselectivity observed in the case of
trickling ﬁlters [42]. Macleod et al. [34] identiﬁed the inﬂuent to be
enriched with S()-atenolol, but the efﬂuent to be racemic [34]. In
addition to atenolol, Nikolai et al. [92] studied the enantioselective
degradation of two other b-blockers: metoprolol and propranolol
during wastewater treatment. All compounds studied were subject
to enantioselective biodegradation. This process was season and
WWTP-dependent indicating that stereoselective degradation
patterns are subject to changes in populations and selectivity of
microbial communities capable of degrading the analyte.
Macleod et al. [34] also studied b-blockers (atenolol, metopro-
lol, propranolol, pindolol, nadolol and sotalol) as well as, SSRI
(citalopram and ﬂuoxetine) and salbutamol during wastewater
treatment. Wastewater inﬂuent was found enriched with R()-
ﬂuoxetine compared to wastewater efﬂuent. Propranolol was
found to be racemic in wastewater inﬂuent and efﬂuent enriched
with S()-propranolol [34]. An enrichment of S(+)-ﬂuoxetine and
S()-propranolol as a result of wastewater treatment is of
potentially signiﬁcant ecotoxicological consequences as S(+)-
ﬂuoxetine and S()-propranolol are more toxic than their
opposing enantiomers to Pimephales promelas [22,23].
Matamoros et al. [50] reported that enantioselective degradation
of S(+)-ibuprofen depends on the oxidation status of WWTP. In
aerobic conditions S(+)-ibuprofen degrades faster than R()-
ibuprofen, whereas no enantioselectivity is observed in anaerobic
conditions. It is suggested that such a situation is a result of the
presence of different bacterial consortia under aerobic and anaerobic
conditions. In contrast the EF of naproxen decreased during
wastewater treatment in the case of both aerobic and anaerobic
processes [50]. Buser et al. [48] also studied the occurrence andFig. 7. Concentrations (shown as symbols) and mean EF values (showbehaviour of ibuprofen during wastewater treatment. Ibuprofen was
found at very high concentrations in WWTP inﬂuents with a high
enantiomeric excess of the pharmacologically active S(+)-enantio-
mer, which signiﬁcantly decreased as a result of wastewater
treatment. A single enantiomer (S(+)) of naproxen is prescribed
and only this enantiomer was present in untreated wastewater along
with o-desmethylnaproxen (EF = 1) [27], however in treated
wastewater the mean EF equaled 0.8, indicating an enrichment
with R()-enantiomer [45,50]. Hashim et al also found the
enrichment of R()Naproxen during a membrane bioreactor [46].
3.2. Enantioselective environmental fate of chiral PACs
The concentrations of chiral PACs recorded in environmental
samples (mainly rivers) are wide spread, (Fig. 7). Pharmaceuticals
are considered pseudo-persistent due to their continuous release
from WWTPs. As has been demonstrated above, although WWTPs
do generally reduce the overall concentration of drugs, the
enantiomeric fraction of released chiral PACs is often not racemic.
Chiral PACs are then exposed to different microbial populations in
surface waters potentially changing the stereoselective degrada-
tion further. Legislation as outlined previously only requires at
most an assessment of parent compounds at the EF which they are
prescribed and/or distributed and is therefore unlikely to give a
true representation of the risks and/or the concentrations
associated with those risks as both pharmacological action and
potency may be disparate between enantiomers.
Enantioselective fate of several amphetamine-like compounds,
antidepressant venlafaxine and beta-blocker atenolol was studied
in a 9 months monitoring programme undertaken by Kasprzyk-
Hordern et al. [42]. The extent of stereoselectivity was dependent
on the type of chiral compound, proximity to wastewater
treatment plants (and utilized technology) and season. Higher
stereoselectivity was observed over the spring/summer time due
to higher microbial activity. MDMA was quantiﬁed in receiving
waters at low ppt levels and it was found to be enriched with R()-
enantiomer, further enrichment with R()-enantiomer was
observed with the course of the river. Amphetamine was also
found in receiving waters enriched with R()-enantiomer. This is
supported by Bagnall et al’s ﬁndings [93] where microcosms weren as bars) recorded in environmental samples [30–32,40,44,51].
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amphetamine and methamphetamine under controlled condition.
Bagnall et al. found that within 5 days the S(+)-amphetamine had
been degraded completely, leaving only R()-amphetamine.
As a result of enrichment of ephedrine with unnatural
1S,2R(+)-enantiomer during wastewater treatment, this enan-
tiomer was also detected in receiving waters, despite the fact
that this enantiomer is not prescribed [42]. In the case of
venlafaxine more signiﬁcant changes in EFs were observed in
receiving waters than in wastewater. This change was season
dependent with the lowest recorded EF for venlafaxine at 0.4 in
December and the highest EF of 0.65 recorded in August. The EFs
of venlafaxine in receiving waters did not always correspond
with EFs of venlafaxine in discharged wastewater efﬂuent. [42].
Non-racemic composition of venlafaxine was also observed by
Bagnall et al. [41].
Similarly atenolol was found to be strongly season dependent,
with enrichment of S()-enantiomer increasing with the ﬂow of
the river in contrast to the enrichment with R(+)-atenolol in the
WWTP. Venlafaxine and atenolol’s altered EF during attenuation in
the environment indicates that stereoselective processes in surface
water are more signiﬁcant than those observed during wastewater
treatment [42] and might involve a different consortia of
microorganisms [42]. Non-racemic composition of atenolol was
also observed by Bagnall et al. [41]. Similarly, another beta-blocker,
metoprolol was found to be non-racemic in rivers. Furthermore, a
decrease of EF values for metoprolol alongside the river (from
EF = 0.5 to EF = 0.44 over travel time = 13 days) was observed [28].
Lopez-Serna et al. [60] also studied a variety of beta-blockers in
surface waters in Spain. Atenolol, sotalol and metoprolol were
usually found in racemic proportions, however propranolol and
ﬂuoxetine were found to be enriched with S()-propranolol and
S(+)-ﬂuoxetine, which may be signiﬁcant considering Stanley
et al’s toxicological papers [22,23] noted previously. In addition
Lopez-Serna also noted albuterol was enriched with one enantio-
mer [60].
Ibuprofen, prescribed as racemic mixture of two enantiomers,
was found with excess of the pharmacologically active S-
enantiomer [48] in surface waters. Winkler et al. [94] studied
ibuprofen in a bioﬁlm reactor with river water and observed much
higher degradation of non-pharmacologically active R-enantio-
mer. This indicates that the principal environmental contaminant
resulting from the use of ibuprofen is S-enantiomer, which is
pharmacologically active to humans and possibly to other species.
3.3. Sewage epidemiology
A newly emerging epidemiology approach to estimate commu-
nity-wide drug use via wastewater analysis was ﬁrst proposed by
Daughton [95], applied by Zuccato et al. [96] and since then a host
of groups have looked into illicit drug use within communities
through the analysis of sewage, including [97]. For more detailed
reviews on this topic please see [95,98]. An expansion of this ﬁeld,
proposed by Kasprzyk-hordern [14], is the inclusion of enantio-
mer-speciﬁc analysis of drugs in sewage which could verify the
method of synthesis being used, identify whether some drugs have
resulted from metabolism of parent compounds or through direct
ingestion e.g. methamphetamine from amphetamine, verify the
route of administration of some compounds, conﬁrm to a greater
degree the potency of illicit drugs on the market, monitor changing
patterns of drugs abuse, distinguish between legal and illicit use of
drugs [14] and in localized studies identify whether drugs are
present through the excretion or disposal of unused drugs. The
results of the ﬁrst study of this kind are very promising and
indicated that amphetamine in raw wastewater was enriched
with R()-enantiomer due to its abuse as racemate. When ingestedas a racemate MDMA is excreted enriched with R()MDMA, this
was observed in inﬂuent suggesting direct consumption, whereas
MDA was enriched with S(+)-enantiomer, suggesting its presence
might be associated with MDMA abuse and not direct MDA
use [14].
3.4. Chiral PACs as chemical markers of water contamination with
sewage
Human sewage contamination in water courses has tradition-
ally been hard to distinguish from legitimate efﬂuent release and
agricultural contamination. A pharmaceutical marker, prescribed
only to humans, may be able to make this distinction [99].
However the distinction between treated and untreated human
waste must be carried out by chiral analysis. A chemical marker
here must be consistent in samples where sewage is found and
must consistently and signiﬁcantly change its EF during its
residency in WWTPs in a way that is not consistent with
attenuation in the environment; i.e. they must have one EF when
in treated sewage efﬂuent and at least one other distinct EF when
in WWTP inﬂuent and/or when attenuated in the environment. To
this end, propranolol was identiﬁed as a possible suitable chemical
marker by Fono et al. [47]. EF changed from 0.49–0.54 in inﬂuent to
0.30–0.44 in efﬂuent suggesting that chiral analysis would be able
to indicate whether the source had been treated in a WWTP or not.
However it is important to also ascertain whether attenuation in
the environment could ‘mimic’ WWTP efﬂuent EF and longer
environmental residence. Fono et al. [47] conﬁrmed a wetland
environment did not change the EF signiﬁcantly, nor did their
surface water microcosm, however further sampling from a wider
variety of ecosystems and distances from discharge points is
needed to conﬁrm this.
Gasser et al. [29] compared the use of enantiomeric fractions
with isotope abundance as a tool for tracking the source of sewage
contamination in the environment. Both EFs and isotope abun-
dances are physically and chemically similar to their counterparts
and quantiﬁed more accurately than if taking whole drug or
isotope concentration. The sensitivity of enantiomer detection may
be slightly higher than isotope analysis, particularly with larger
molecules, but the main difference between them results from
isotope selectivity occurring under abiotic as well as biotic
conditions. Enantioselectivity on the other hand indicates that
biological degradation must have occurred. Isotope excess may
have other advantages over measuring EF, such as a more
predictable degradation pattern [29]. Thus the information from
both sources may be complementary.
3.5. Chiral PACs as indicators for environmental biotransformation
Enantioselective analysis of pharmaceuticals in the environ-
ment can also be used to provide more detailed information on the
degradation processes within various ecosystems [30]. Stereo-
selective changes in a compound once it has been released into the
environment indicate biological interactions play a role in its
degradation, although it should be noted that this may involve the
cleavage of conjugates to form additional parent drugs. However
no stereoselectivity in a compound after it is released into the
environment does not necessarily indicate achiral degradation is
the dominant mechanism as not all biological degradation is
stereoselective. Pharmaceutical enantiomeric degradation in
differing environmental samples has been examined by Buser
(ibuprofen) [48], Selke (naproxen and desmethyl naproxen) [27],
Fono (propranolol) [28] and Kasprzyk-Hordern (amphetamine,
methamphetamine, venlafaxine, atenolol, MDMA, MDA)[42].
Stereoselective degradation has been observed in ibuprofen, and
this EF change increased during warmer months. The ibuprofen
S.E. Evans, B. Kasprzyk-Hordern / Trends in Environmental Analytical Chemistry 1 (2014) e34–e51e50was quantiﬁable in most lake samples but not in the marine
sample or lake with 17 year residency time [48]. In addition to
environmental samples, Fono et al. [47] also carried out some
microcosm studies which conﬁrmed that a combination of
biological and photodegradation resulted in the reduced concen-
tration of propranolol in environmental samples [47]. Selke et al.
[27] concluded that O-desmethylnaproxen was non-stereoselec-
tively formed from naproxen within environmental conditions,
although the mechanism for this is not established.
4. Conclusions
Stereoselective environmental analysis of pharmaceuticals is an
emerging area and there are several large gaps in knowledge in this
ﬁeld. The most important problem which needs urgent attention is
the lack of standardization of sample collection, storage, prepara-
tion, analysis and ﬁnally interpretation of the results obtained.
Although approaches utilized in non-chiral chromatography for
environmental analysis of pharmaceuticals are also fully applica-
ble to chiral analysis, special attention has to be paid to all
procedures potentially responsible for enantioselective processes
(e.g. microbial activity during sample collection and storage or
matrix effect in ESI) throughout the whole analytical process. It is
therefore of the utmost importance to use appropriate procedures
for the quantiﬁcation of enantiomers, utilizing preferably labelled
internal standards.
Signiﬁcant advances are also needed to increase the speed of
analysis and column efﬁciency. This could be done via the
introduction of chiral stationary phases with sub-2 mm particle
size technology. It is also of great importance to develop columns
that show very good enantioselectivity but also with the capability
to resolve as wide a spectrum of compounds as possible.
This paper has reviewed the current state-of-the-art techniques
as well as the advantages and pitfalls of enantiomer-speciﬁc
analytical methodology developed and utilized in the environ-
mental ﬁeld. It also brieﬂy discussed some of the most exciting
applications of chiral environmental analysis and recommended
harmonized standards and the direction of future work within the
ﬁeld. Further reading into this topic is recommended at [58,59,61–
64,79,81,85,86,98].
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